Abstract
The ocular delivery of drugs encounters several limitations because of the dynamic and static barriers of the human’s eye anatomy and physiology. The poor bioavailability of drugs are mainly related to the topical administration, i.e. eye drops which is the most common drug dosage form for the treatment of eye pathologies. Precorneal factors and drug limitations related to its solubility and susceptibility for physicochemical degradation could be the main reasons for the poor permeation and uptake in the ocular mucosa. Pathologies affecting the anterior and posterior segment of the eye are thereafter difficult to be treated and, given the chronic and degenerative nature of some of these injuries, it is crucial to improve drugs therapeutic effect. Nanotechnology-based delivery systems could be a suitable approach to overcome these limitations. Some of the most important colloidal systems are highlighted in this review, such as the use of mucoadhesive polymers, prodrugs, nanogels, liposomes, microemulsions, lipid and polymeric nanoparticles, cyclodextrins, dendrimers and nanocrystals, along with their clinical and therapeutic relevance for the administration of drugs for ocular delivery.
Keywords: Colloidal systems, nanomedicines, nanoparticles, nanotechnology, ocular drug delivery, ocular therapy.
Current Pharmaceutical Design
Title:Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye
Volume: 22 Issue: 9
Author(s): Joana F. Fangueiro, Francisco Veiga, Amelia M. Silva and Eliana B. Souto
Affiliation:
Keywords: Colloidal systems, nanomedicines, nanoparticles, nanotechnology, ocular drug delivery, ocular therapy.
Abstract: The ocular delivery of drugs encounters several limitations because of the dynamic and static barriers of the human’s eye anatomy and physiology. The poor bioavailability of drugs are mainly related to the topical administration, i.e. eye drops which is the most common drug dosage form for the treatment of eye pathologies. Precorneal factors and drug limitations related to its solubility and susceptibility for physicochemical degradation could be the main reasons for the poor permeation and uptake in the ocular mucosa. Pathologies affecting the anterior and posterior segment of the eye are thereafter difficult to be treated and, given the chronic and degenerative nature of some of these injuries, it is crucial to improve drugs therapeutic effect. Nanotechnology-based delivery systems could be a suitable approach to overcome these limitations. Some of the most important colloidal systems are highlighted in this review, such as the use of mucoadhesive polymers, prodrugs, nanogels, liposomes, microemulsions, lipid and polymeric nanoparticles, cyclodextrins, dendrimers and nanocrystals, along with their clinical and therapeutic relevance for the administration of drugs for ocular delivery.
Export Options
About this article
Cite this article as:
Fangueiro F. Joana, Veiga Francisco, Silva M. Amelia and Souto B. Eliana, Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye, Current Pharmaceutical Design 2016; 22 (9) . https://dx.doi.org/10.2174/1381612822666151216145900
DOI https://dx.doi.org/10.2174/1381612822666151216145900 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Polyphenols and Cardioprotection
Mini-Reviews in Medicinal Chemistry Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry <i>In-Silico</i> and <i>In-Vitro</i> Analysis of Human <i>SOS1</i> Protein Causing Noonan Syndrome - A Novel Approach to Explore the Molecular Pathways
Current Genomics Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Oncogenic Properties of HIV-Tat in Colorectal Cancer Cells
Current HIV Research Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Current Medicinal Chemistry Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes
Current Vascular Pharmacology Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy Signal Transduction Targets in Prostate Cancer
Current Signal Transduction Therapy Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Viral Origins of Human Cancer
Current Medicinal Chemistry Overview on the Tricks of HIV Tat to Hit the Blood Brain Barrier
Current HIV Research Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities
Current Pharmaceutical Design Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities
Current Topics in Medicinal Chemistry Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Current Pharmaceutical Design